2025-03-10
Eli Lilly CEO David Rick’s’ pay rose to nearly $30 million in 2024
Eli Lilly (LLY) CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the most valuable pharmaceutical company in the world.
[...]Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
2025-03-05
Digg is getting another revival, this time with an injection of AI
Digg is getting another reboot with two of the most prominent names of the Web 2.0 era leading the charge. Founder Kevin Rose has bought it back for an undisclosed sum. Rose’s partner in this endeav [...]
2025-03-14
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup
An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. sen [...]
2025-03-27
Eli Lilly's online health platform just expanded beyond weight loss to tackle Alzheimer’s
Just about a year after launching a direct-to-consumer online platform to sell treatments for diabetes and obesity, Eli Lilly (LLY) is now expanding the program to offer resources for Alzheimer’s d [...]
2025-01-16
The best live TV streaming services to cut cable in 2025
Around ten years ago, as the price of cable rose to untenable heights, live TV streaming services arrived as the low-cost, contract-free antidote. The services are still blissfully easy to walk away f [...]
2025-04-18
Eli Lilly promises to make new weight-loss pill in the U.S.
Eli Lilly (LLY) CEO Dave Ricks said Friday that the company will make its planned GLP-1 weight-loss pill in the U.S. amid President Donald Trump’s sweeping tariffs and his push to get companies to [...]
2025-03-28
Eli Lilly's Alzheimer's drug is rejected by EU regulators over brain swelling risk, despite U.S. approval
The European Union’s health regulator on Friday rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, citing risks of brain swelling and bleeding. It’s a major setback for the company as it co [...]
